- cafead Oct 25, 2022 at 11:02: AM
via Vaxxinity has concluded subject enrolment in its Phase III pivotal clinical trial of Covid-19 vaccine, UB-612, as a heterologous booster.
UB-612 is being analysed as a booster following an initial regimen with messenger ribonucleic acid (mRNA), adeno-vectored, and inactivated vaccines.
article source
UB-612 is being analysed as a booster following an initial regimen with messenger ribonucleic acid (mRNA), adeno-vectored, and inactivated vaccines.
article source